Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
The DOI matches its Crossref record; 120 of the 121 references it cites were found in a registry or an index.
Abstract
The opposing actions of histone acetyltransferases (HATs) and histone deacetylases (HDACs) allow gene expression to be exquisitely regulated through chromatin remodelling. Aberrant transcription due to altered expression or mutation of genes that encode HATs, HDACs or their binding partners, is a key event in the onset and progression of cancer. HDAC inhibitors can reactivate gene expression and inhibit the growth and survival of tumour cells. The remarkable tumour specificity of these compounds, and their potency in vitro and in vivo, underscore the potential of HDAC inhibitors as exciting new agents for the treatment of cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Acetylation of the core histones of nucleosomes strongly influences gene transcription (Khochbin et al., 2001; Johnstone, 2002).”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Johnstone, 2002
In the citing paper
“Class I HDACs are ubiquitously expressed and are primarily located in the nucleus, while the class II enzymes can shuttle between the nucleus and cytoplasm and demonstrate tissue-specific expression (Johnstone, 2002; Marks et al., 2001; Vigushin and Coombes, 2002).”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Johnstone, 2002
In the citing paper
“Two related classes of eukaryotic zinc-containing HDACs have been recognized based upon sequence similarity: class I (HDAC1, 2, 3, and 8) and class II (HDAC4, 5, 6, 7, 9, and 10) (Johnstone, 2002; Gao et al., 2002).”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Johnstone, 2002
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Jenuwein, T., & Allis, C. D. (2001) · Science · doi:10.1126/science.1063127 · Cited by 9,756 · cited 1×
“In general terms, condensed chromatin mediates transcriptional repression, whereas transcriptionally active genes are in areas of open chromati”
BackgroundCrystal structure of the nucleosome core particle at 2.8 Å resolution
Luger, K., Mäder, A. W., Richmond, R. K., Sargent, D. F., & Richmond, T. J. (1997) · Nature · doi:10.1038/38444 · Cited by 9,466
Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase
Imai, S.-I., Armstrong, C. M., Kaeberlein, M., & Guarente, L. (2000) · Nature · doi:10.1038/35001622 · Cited by 3,510 · cited 1×
“pl?locus=sir2">Sir2 , a yeast transcriptional repressor that requires the cofactor NAD + for its deacetylase activit”
BackgroundhSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase
Vaziri, H., Dessain, S. K., Eaton, E. N., Imai, S.-I., Frye, R. A., Pandita, T. K., Guarente, L., & Weinberg, R. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00527-x · Cited by 2,659 · cited 3×
“Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of DAXX in acute promyelocytic leukaemia with t(15;17).”
Negative Control of p53 by Sir2α Promotes Cell Survival under Stress
Luo, J., Nikolaev, A. Y., Imai, S.-I., Chen, D., Su, F., Shiloh, A., Guarente, L., & Gu, W. (2001) · Cell · doi:10.1016/s0092-8674(01)00524-4 · Cited by 2,081
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Gottlicher, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6969 · Cited by 1,887 · cited 1×
“asp?DrugCode=1%2D1882&DrugName=VALPROIC+ACID+ORAL&DrugType=1">valproic acid , inhibit HDAC activity and affect the expression of numerous genes with disparate cellular function”
BackgroundHistone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866 · cited 1×
“gov/cancer_information/cancer_type/leukemia/">leukaemias and solid tumours to express differentiated characteristics and stop proliferatin”
BackgroundCameron, E. E., Bachman, K. E., Myöhänen, S., Herman, J. G., & Baylin, S. B. (1999) · Nature Genetics · doi:10.1038/5047 · Cited by 1,857
Acetylation of Histones and Transcription-Related Factors
Sterner, D. E., & Berger, S. L. (2000) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.64.2.435-459.2000 · Cited by 1,780 · cited 5×
“Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins.”
BackgroundInfluential
Research works printed but not linked: 1
- Ruefli, A. A. Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-gp expressing cells. Int. J. Cancer. (in the press).
Cited by
Items 501–600 of 1,001
Guzmán, M. L., Yang, N., Sharma, K. K., Balys, M. M., Corbett, C. A., Jordan, C. T., Becker, M. W., Steidl, U. G., Abdel-Wahab, O. I., Levine, R. L., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0963 · Cited by 56
“This compound is 26% orally bioavailable (21) and demonstrates significant antitumor properties (17).”
BackgroundA Wrench-Shaped Synthetic Molecule that Modulates a Transcription Factor−Coactivator Interaction
Shimogawa, H., Kwon, Y., Mao, Q., Kawazoe, Y., Choi, Y., Asada, S., Kigoshi, H., & Uesugi, M. (2004) · Journal of the American Chemical Society · doi:10.1021/ja038855+ · Cited by 55
Histone deacetylase–mediated silencing of AMWAP expression contributes to cisplatin nephrotoxicity
Ranganathan, P., Hamad, R., Mohamed, R., Jayakumar, C., Muthusamy, T., & Ramesh, G. (2016) · Kidney International · doi:10.1038/ki.2015.326 · Cited by 55
“HDAC inhibitors are commonly used for the treatment of several cancers [16] where they sensitize cancers to apoptosis.”
TET3 Inhibits Type I IFN Production Independent of DNA Demethylation
Xue, S., Liu, C., Sun, X., Li, W., Zhang, C., Zhou, X., Lu, Y., Xiao, J., Li, C., Xu, X., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.06.068 · Cited by 59
FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70
Wang, Y., Wang, S., Zhang, X., Zhao, M., Hou, C., Xu, Y.-J., Du, Z., & Yu, X. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.03.076 · Cited by 59
Sp1-Mediated TRAIL Induction in Chemosensitization
Xu, J., Zhou, J.-Y., Wei, W.-Z., Philipsen, S., & Wu, G. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0657 · Cited by 56
“To determine the underlying mechanisms by which MS275 sensitizes T47D cells to Adriamycin, we tested the activation of the apoptotic pathways because HDAC inhibitors can kill cancer cells by apoptosis (25).”
BackgroundRadiation and New Molecular Agents, Part II: Targeting HDAC, HSP90, IGF-1R, PI3K, and Ras
Chinnaiyan, P., Allen, G., & Harari, P. M. (2005) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2005.08.008 · Cited by 62
The acetylation of transcription factor HBP1 by p300/CBP enhances p16INK4A expression
Wang, W., Pan, K., Chen, Y., Huang, C., & Zhang, X. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr818 · Cited by 54
Zhao, Z., Bai, J., Zhou, Q., Yan, B., Qin, W., Jia, L., Meng, Y., Jin, B., Yao, L.-B., Wang, T., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045133 · Cited by 56
“HDAC inhibitors have been shown to exert various anti-tumor effects, such as growth inhibition, the induction of apoptosis or differentiation, and the blocking of angiogenesis in vivo [7,8].”
BackgroundMitochondrial–nuclear epistasis: Implications for human aging and longevity
Tranah, G. J. (2011) · Ageing Research Reviews · doi:10.1016/j.arr.2010.06.003 · Cited by 54
Carboxypeptidase 4 gene variants and early-onset intermediate-to-high risk prostate cancer
Ross, P., Cheng, I. C., Liu, X., Cicek, M. S., Carroll, P. R., Casey, G., & Witte, J. S. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-69 · Cited by 54
“[16,17] They have been shown to modify the expression of different genes, inhibit the cell cycle, and induce apoptosis in several cell lines.[18] Therefore, there is a potential biological basis to suspect that the rs2171492 SNP may alter the function of CPA4 with alterations in cell cycle regulation and potential car…”
BackgroundEpigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review
Smith, H. J., Straughn, J. M., Buchsbaum, D. J., & Arend, R. C. (2017) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2017.03.007 · Cited by 56
“Importantly, when compared to tumor cells, normal cells are relatively resistant to the effects of HDAC inhibitors (Johnstone, 2002).”
BackgroundXue, Y., Lian, W., Zhi, J., Yang, W., Li, Q., Guo, X., Gao, J., Qu, H., Lin, W., Li, Z., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0625-0 · Cited by 58
Mirzaei, S., Gholami, M. H., Ang, H. L., Hashemi, F., Zarrabi, A., Zabolian, A., Hushmandi, K., Delfi, M., Khan, H. Z., Ashrafizadeh, M., et al. (2021) · Cells · doi:10.3390/cells10123348 · Cited by 57
“HDAC dysregulation is associated with transcription repression and inhibiting expression of tumor-suppressor genes [134,135].”
BackgroundHistone Deacetylase Inhibitors in Cancer Therapy
Fouladi, M. (2006) · Cancer Investigation · doi:10.1080/07357900600814979 · Cited by 57
“HDAC inhibitors are chromatin remodelling agents which activate transcription of genes leading to cellular differentiation, inhibition of cell cycle progression and induction of apoptosis (41).”
BackgroundHistone deacetylase inhibitors for epigenetic therapy of cancer
Monneret, C. (2007) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328012a5db · Cited by 59
Sonnemann, J., Gänge, J., Kumar, K. S., Müller, C., Bader, P., & Beck, J. F. (2005) · Investigational New Drugs · doi:10.1007/s10637-005-5854-9 · Cited by 56
“They function by inhibiting histone deacetylases, resulting in the accumulation of acetylated histones, leading to an increase in transcriptionally active chromatin [9].”
BackgroundA Review on Fruit and Vegetable Fermented Beverage-Benefits of Microbes and Beneficial Effects
Tang, Z., Zhao, Z., Wu, X., Lin, W., Qin, Y., Chen, H., Wan, Y., Zhou, C., Bu, T., Chen, H., et al. (2022) · Food Reviews International · doi:10.1080/87559129.2021.2024222 · Cited by 57
Alam, Z., Shang, X., Effat, K., Kanwal, F., He, X., Li, Y., Xu, C., Niu, W., War, A. R., & Zhang, Y. (2022) · Journal of Food Biochemistry · doi:10.1111/jfbc.14302 · Cited by 62
Mechanisms of HDAC inhibitor-induced thrombocytopenia
Matsuoka, H., Unami, A., Fujimura, T., Noto, T., Takata, Y., Yoshizawa, K., Mori, H., Aramori, I., & Mutoh, S. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.06.015 · Cited by 56
The therapeutic uses of chromatin-modifying agents
Mai, A. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.6.835 · Cited by 63
“1 Class I/class II HDAC inhibitors Since the discovery that the antileukaemia properties of trichostatin A (TSA) are due to inhibition of HDAC enzymes [54], a great number of structurally different HDACi have been reported as novel antiproliferative and cytodifferentiating agents (Figure 2) [55-57].”
BackgroundBian, X., Liang, Z., Feng, A., Salgado, E., & Shim, H. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.11.008 · Cited by 55
“Previous studies have shown that HDAC inhibitors could reactivate gene expression and inhibit the growth and survival of tumor cells, underlying the potential of HDAC inhibitors as exciting new agents for the treatment of cancer [43].”
Al-Sanea, M. M., Gotina, L., Mohamed, M. F. A., Parambi, D. G. T., Anwar, H., Mathew, B., Youssif, B. G. M., Alharbi, K. S., Elsayed, Z. M., Abdelgawad, M. A., et al. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s237957 · Cited by 56
“The first one is the zinc-binding group (ZBG) that coordinates the Zn at the bottom of the enzyme cavity; the second one is a cap group (CAP) that interacts with the rim of the catalytic tunnel of the enzyme; the third one is a polar connection unit (CU, apparently dispensable for HDAC8 selective inhibitors) connectin…”
Tian, T., Zhao, Y., Yang, Y., Wang, T., Jin, S., Guo, J., & Liu, Z. (2020) · PubMed Central · Cited by 68
Mei, Q.-B. (2012) · Oncology Reports · doi:10.3892/or.2012.1793 · Cited by 59
Histone Deacetylase Inhibition by Sodium Valproate Regulates Polarization of Macrophage Subsets
Wu, C., Li, A., Leng, Y., Li, Y., & Kang, J. (2011) · DNA and Cell Biology · doi:10.1089/dna.2011.1401 · Cited by 58
“…(HDACs) and histone acetyl-transferases play critical roles in controlling the dynamics of chromatin structure by regulating histone acetylation (Johnstone, 2002; Narlikar et al. , 2002), while chromatin structure alteration is essential in controlling gene transcription and the consequent…”
Does microglial dysfunction play a role in autism and Rett syndrome?
Maezawa, I., Calafiore, M., Wulff, H., & Jin, L. (2011) · Neuron Glia Biology · doi:10.1017/s1740925x1200004x · Cited by 59
“A variety of environmental toxins with known adverse impacts on human neurodevelopment have been investigated for their potential effects on DNA methylation and other epigenetic effects (Baccarelli and Bollati, 2009).”
BackgroundInfluentialIgaz, N., Kovács, D., Rázga, Z., Kónya, Z., Boros, I., & Kiricsi, M. (2016) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2016.07.004 · Cited by 54
Histone deacetylase inhibition is associated with transcriptional repression of the Hmga2 gene
Ferguson, M. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg403 · Cited by 52
Park, J., Jong, H.-S., Kim, S. G., Jung, Y., Lee, K., Lee, J., Kim, D., Bang, Y., & Kim, T. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0260-8 · Cited by 55
“Histone deacetylase inhibitors (HDIs) induce cell cycle arrest, differentiation, and apoptosis in a variety of tumor cells, both in vitro and in vivo [1, 2].”
BackgroundHeterocyclic ketones as inhibitors of histone deacetylase
Vasudevan, A., Ji, Z., Frey, R. R., Wada, C. K., Steinman, D. H., Heyman, H. R., Guo, Y. P., Curtin, M. L., Guo, J., Li, J., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.09.007 · Cited by 56
Chobanian, N. H., Greenberg, V. L., Gass, J. M., DeSimone, C. P., van Nagell, J. R., & Zimmer, S. G. (2004) · PubMed · Cited by 59
Newbold, A., Salmon, J. M., Martin, B. P., Stanley, K., & Johnstone, R. W. (2013) · Oncogene · doi:10.1038/onc.2013.482 · Cited by 61
Self-citationIslam, R., Dash, D., & Singh, R. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155720 · Cited by 55
A review on quinolines: New green synthetic methods and bioactive potential
Ferreira, L. M., García, P. G., García, P. A., & Castro, M. A. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107097 · Cited by 54
Zhao, L., Wang, Y.-Q., Cao, D., Chen, T., Wang, Q., Li, Y., Xu, Y., Zhang, N., Wang, X., Chen, D., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501504k · Cited by 54
Therapeutic Effect of Histone Deacetylase Inhibitor, Sodium Butyrate, on Allergic Rhinitis In Vivo
Wang, J., Wen, L., Wang, Y., & Chen, F. (2016) · DNA and Cell Biology · doi:10.1089/dna.2015.3037 · Cited by 56
“Overexpression of HDACs results in abnormal hy-poacetylation of histones, leading to a variety of cancers (Johnstone, 2002; Minucci and Pelicci, 2006; Delatouche et al. , 2013).”
Brożek-Płuska, B., Musiał, J., Kordek, R., & Abramczyk, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143398 · Cited by 53
Negmeldin, A. T., Knoff, J. R., & Pflum, M. K. H. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.076 · Cited by 52
“HDAC inhibitors promoted apoptosis and reduced proliferation and migration through their effect on both histone and non-histone substrates.[17-19].”
BackgroundMai, A., Massa, S., Rotili, D., Pezzi, R., Bottoni, P., Scatena, R., Meraner, J., & Brosch, G. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.07.081 · Cited by 53
Magnaghi-Jaulin, L., Éot-Houllier, G., Fulcrand, G., & Jaulin, C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3012 · Cited by 54
Small-Molecule Inhibitors Overcome Epigenetic Reprogramming for Cancer Therapy
Xiao, W., Zhou, Q., Wen, X., Wang, R., Liu, R., Wang, T., Shi, J., Hu, Y., & Hou, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.702360 · Cited by 51
“Then, more HDACis were discovered from natural products, which Frontiers in Pharmacology | www.frontiersin.org September 2021 | Volume 12 | Article 70236013 have different properties and clinical settings (Johnstone, 2002; West and Johnstone, 2014).”
BackgroundParsana, N., Kumar, S., Aswal, V. K., Seoud, O. A. E., & Malek, N. I. (2022) · ACS Applied Engineering Materials · doi:10.1021/acsaenm.2c00095 · Cited by 50
Oku, N., Nagai, K., Shindoh, N., Terada, Y., van Soest, R. W. M., Matsunaga, S., & Fusetani, N. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.02.062 · Cited by 50
Interplay of bromodomain and histone acetylation in the regulation of p300-dependent genes
Chen, J., Ghazawi, F. M., & Li, Q. (2010) · Epigenetics · doi:10.4161/epi.5.6.12224 · Cited by 55
Mühlethaler‐Mottet, A., Flahaut, M., Bourloud, K. B., Auderset, K., Meier, R., Joseph, J., & Groß, N. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-214 · Cited by 50
“HDACIs mechanism of action appears to involve cell cycle arrest, induction of apoptosis and differentiation both in vitro and in vivo [21,22].”
Ko, H., Jeong, M., Jeon, H., Sung, G., So, Y., Kim, I., Son, J., Lee, S.-W., Yoon, H., & Choi, K. (2015) · Oncotarget · doi:10.18632/oncotarget.3667 · Cited by 54
“Because most agents used in such combinations are inherently toxic, it is imperative to find nontoxic agents, such as HDAC inhibitors (HDACi), which have recently entered clinical trials and exert their antitumor effects by inducing growth arrest, differentiation, and apoptosis [41-44].”
BackgroundTilekar, K. N., Upadhyay, N., Jänsch, N., Schweipert, M., Mrówka, P., Meyer‐Almes, F., & Ramaa, C. S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103522 · Cited by 52
Ragno, R., Mai, A., Massa, S., Cerbara, I., Valente, S., Bottoni, P., Scatena, R., Jesacher, F., Loidl, P., & Brosch, G. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm031036f · Cited by 56
HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2
Scognamiglio, A., Nebbioso, A., Manzo, F., Valente, S., Mai, A., & Altucci, L. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.07.007 · Cited by 56
Retinoic-acid-induced apoptosis in leukemia cells
Jimenez-Lara, A. M., Clarke, N., Altucci, L., & Gronemeyer, H. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.08.006 · Cited by 59
Hainsworth, J. D., Daugaard, G., Lesimple, T., Hübner, G., Greco, F. A., Stahl, M., Büschenfelde, C. M. Z., Allouache, D., Penel, N., Knoblauch, P., et al. (2015) · Cancer · doi:10.1002/cncr.29229 · Cited by 51
“Inhibition of the family of HDACs leads to acetylation of multiple nuclear proteins; the subsequent induction of genes involved in cell cycle regulation; and subsequent induction of growth arrest, cellular differentiation, and apoptosis.(12,13,31,32) In addition to the potential for single-agent activity, preclinical…”
BackgroundFeng, W., Cai, D., Zhang, B., Lou, G., & Zou, X. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.08.017 · Cited by 49
The role of epigenetics in malignant pleural mesothelioma
Vandermeers, F., Sriramareddy, S. N., Costa, C., Hubaux, R., Cosse, J.-P., & Willems, L. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.05.014 · Cited by 51
Genetics, Nutrition, and Health: A New Frontier in Disease Prevention
Agrawal, P., Kaur, J., Singh, J., Rasane, P., Sharma, K., Bhadariya, V., Kaur, S., & Kumar, V. (2023) · Journal of the American Nutrition Association · doi:10.1080/27697061.2023.2284997 · Cited by 67
Epigenetic mechanisms of plant-derived anticancer drugs
Schneider‐Stock, R., Ghantous, A., Bajbouj, K., Saikali, M., & Darwiche, N. (2011) · Frontiers in bioscience · doi:10.2741/3919 · Cited by 50
Bayat, S., Derakhshan, S. M., Derakhshan, N. M., Khaniani, M. S., & Alivand, M. R. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28193 · Cited by 52
Yao, D., Li, C., Jiang, J., Huang, J. M., Wang, J., He, Z., & Zhang, J. C. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112648 · Cited by 48
From natural products to HDAC inhibitors: An overview of drug discovery and design strategy
Qiu, X., Zhu, L., Wang, H., Tan, Y. L., Yang, Z., Yang, L., & Wan, L. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116510 · Cited by 52
Fang, J., Chen, Y., Lü, J., Rong, L. U., Yang, L., Zhu, H. Y., Wei Qi, G. U., & Lu, L. (2004) · Cell Research · doi:10.1038/sj.cr.7290222 · Cited by 53
Eyal, S., Yagen, B., Shimshoni, J. A., & Bialer, M. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.02.012 · Cited by 53
Recent Advances in Cancer Therapeutics
Chessum, N. E. A., Jones, K., Pasqua, E., & Tucker, M. (2015) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2014.11.002 · Cited by 53
Berger, I., Bieniossek, C., Schaffitzel, C., Hassler, M., Santelli, E., & Richmond, T. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301646200 · Cited by 48
Riester, D., Hildmann, C., & Schwienhorst, A. (2007) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-007-0912-1 · Cited by 55
“…following, due to space limitations, only some examples of the different modes of HDAC inhibitor action are discussed in some detail (for a more comprehensive review, see Johnstone 2002; Vigushin and Coombes 2002; Bi and Jiang 2006; Huang 2006; Kouraklis et al. 2006; and Quaissi and Quaissi 2006).”
BackgroundInfluentialQT Prolongation and Oncology Drug Development
Fradley, M. G., & Moslehi, J. J. (2015) · Cardiac Electrophysiology Clinics · doi:10.1016/j.ccep.2015.03.013 · Cited by 48
Park, H., Kim, S., Kim, Y. E., & Lim, S. (2010) · ChemMedChem · doi:10.1002/cmdc.200900500 · Cited by 52
Epigenetics Modifications and Therapeutic Prospects in Human Thyroid Cancer
Catalano, M. G., Fortunati, N., & Boccuzzi, G. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00040 · Cited by 59
“Depsipeptide Depsipeptide (FK228 or FR901228) is a cyclic peptide that inhibits histone deacetylase activity at nanomolar concentrations (Johnstone, 2002).”
BackgroundGatla, H. R., Zou, Y., Uddin, M. M., Singha, B., Bu, P., Vančura, A., & Vancurova, I. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.771014 · Cited by 50
“Inhibition of HDACs with small molecules has led to the development of HDAC inhibitors (HDIs), which have been used in the treatment of hematological malignancies because they exhibit excellent differential action on normal and cancer cells at therapeutic dosages (19, 20).”
BackgroundThe Molecular Basis of Toxins’ Interactions with Intracellular Signaling via Discrete Portals
Lahiani, A., Yavin, E., & Lazarovici, P. (2017) · Toxins · doi:10.3390/toxins9030107 · Cited by 54
“A major concern for the long term is that HDAC inhibitors may have the potential for activation of oncogenes or epigenetically silenced genes [333].”
BackgroundInfluentialZhang, I., Beus, M., Stochaj, U., Le, P. U., Zorc, B., Rajić, Z., Petrecca, K., & Maysinger, D. (2018) · Cell Death Discovery · doi:10.1038/s41420-018-0103-0 · Cited by 49
Epigenetic Regulation of TRAIL Signaling: Implication for Cancer Therapy
Elmallah, M. I. Y., & Micheau, O. (2019) · Cancers · doi:10.3390/cancers11060850 · Cited by 53
“Besides histones, HDACs can also deacetylate non-histone proteins, some of which are transcription factors such as E2F1, c-Jun, GATA1, TFIIE, TFIIF, p65 (RelA), transcription repressors like Yin Yang 1, Mad/Max, the tumor suppressor gene p53 [12,15,16], and the oncogene c-Myc [17] to cite a few.”
BackgroundHistone deacetylase inhibitors suppress IFNα-induced up-regulation of promyelocytic leukemia protein
Dobrovolná, J., Nováková, Z., Rossmeislová, L., Kahle, M., Hozák, P., & Hodný, Z. (2006) · Blood · doi:10.1182/blood-2006-02-003418 · Cited by 59
Fu, J., Yang, Y., Zhang, X., Mao, W.-J., Zhang, Z., & Zhu, H. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.10.049 · Cited by 54
Lakshmikanthan, V., Kaddour‐Djebbar, I., Lewis, R. W., & Kumar, M. V. (2006) · International Journal of Cancer · doi:10.1002/ijc.21824 · Cited by 54
“HDACi inhibit tumor growth both in vivo and in vitro at nontoxic doses.(8,9) HDACi exert their antitumor effects by their ability to induce growth arrest, differentiation and apoptosis.”
BackgroundBlockade of the ERK pathway markedly sensitizes tumor cells to HDAC inhibitor-induced cell death
Ozaki, K., Minoda, A., Kishikawa, F., & Kohno, M. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.11.131 · Cited by 47
Carol, H., Gorlick, R. G., Kolb, E. A., Morton, C. L., Manesh, D. M., Keir, S. T., Reynolds, C. P., Kang, M. H., Maris, J. M., Wozniak, A. W., et al. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24724 · Cited by 47
“HDAC inhibition induces a plethora of gene expression changes in cancer cells that may lead to these effects [10], with increases in levels of the cell cycle regulator p21 being commonly reported as a consequence of HDAC inhibition [11,12].”
BackgroundEmerging molecular therapies of advanced thyroid cancer
Catalano, M. G., Poli, R., Pugliese, M., Fortunati, N., & Boccuzzi, G. (2010) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2010.02.006 · Cited by 52
Sun, S., Han, Y., Liu, J., Fang, Y., Tian, Y., Zhou, J., Ma, D., & Wu, P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091610 · Cited by 54
“HDACI-mediated tumor cell apoptosis was restored by the overexpression of Bcl2, although G2-M phase arrest was unaltered [28].”
BackgroundMolecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities
Newbold, A., Matthews, G. M., Bots, M., Cluse, L. A., Clarke, C. J. P., Banks, K.-M., Cullinane, C., Bolden, J. E., Christiansen, A. J., Dickins, R. A., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0626 · Cited by 46
“A large number HDAC inhibitors (HDACi) have been developed that can suppress HDAC enzymatic activity and mediate protein acetylation (1, 2).”
BackgroundSelf-citationGupta, S. P. (2015) · Chemical Reviews · doi:10.1021/cr500483r · Cited by 49
Combining Oncolytic Virotherapy with p53 Tumor Suppressor Gene Therapy
Bressy, C., Hastie, E. L., & Grdzelishvili, V. Z. (2017) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2017.03.002 · Cited by 58
Gao, Y., Zhang, C., Chang, J., Yang, C., Liu, J., Fan, S., & Ren, C. (2019) · Biomaterials Science · doi:10.1039/c8bm01422a · Cited by 47
Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric Cancer
Slavish, P. J., Chi, L., Yun, M., Tsurkan, L. G., Martinez, N. E., Jonchère, B., Chai, S. C., Connelly, M., Waddell, M. B., Das, S., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3934 · Cited by 49
“However, the identified lead compound, SJ599 (2), showed only modest BD2-selectivity and the 2-furan group would be a liability for in vivo use.”
BackgroundChianese, A., Santella, B., Ambrosino, A., Stelitano, D., Rinaldi, L., Galdiero, M., Zannella, C., & Franci, G. (2021) · Cancers · doi:10.3390/cancers13112761 · Cited by 50
Discovery of pomalidomide-based PROTACs for selective degradation of histone deacetylase 8
Sun, Z., Deng, B., Yang, Z., Mai, R., Huang, J., Ma, Z., Chen, T., & Chen, J. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114544 · Cited by 46
VanOosten, R. L., Earel, J. K., & Griffith, T. S. (2006) · APOPTOSIS · doi:10.1007/s10495-006-0009-9 · Cited by 47
“[52–54].”
Biological Activities in Animal Models.
Mori, H., Abe, F., Furukawa, S., Furukawa, S., Sakai, F., Hino, M., & Fujii, T. (2003) · The Journal of Antibiotics · doi:10.7164/antibiotics.56.80 · Cited by 47
Chromatin Modifications as Targets for New Anticancer Drugs
Schäfer, S., & Jung, M. (2005) · Archiv der Pharmazie · doi:10.1002/ardp.200500984 · Cited by 60
Molecularly targeted therapy for melanoma
Becker, J. C., Kirkwood, J. M., Agarwala, S. S., Dummer, R., Schrama, D., & Hauschild, A. (2006) · Cancer · doi:10.1002/cncr.22273 · Cited by 46
Pigeon, P., Top, S., Vessières, A., Huché, M., Görmen, M., Arbi, M. E., Plamont, M., McGlinchey, M. J., & Jaouen, G. (2011) · New Journal of Chemistry · doi:10.1039/c1nj20192a · Cited by 45
He, L., Gao, L., Shay, C., Lang, L., Lv, F., & Teng, Y. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1080-8 · Cited by 46
McCaw, T. R., Li, M., Starenki, D., Liu, M., Cooper, S. J., Arend, R. C., Forero, A., Buchsbaum, D. J., & Randall, T. D. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02430-9 · Cited by 50
de Freitas, N. L., Deberaldini, M. G., Gomes, D., Pavan, A. R., Sousa, Â., dos Santos, J. L., & Soares, C. P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.592868 · Cited by 49
“In humans, 18 isoforms of HDAC have been described and subdivided in four main classes (Johnstone, 2002; Fass et al., 2013).”
BackgroundJain, M., Marfatia, A., Imam, N., Ray, D., Aswal, V. K., Patel, N. Y., Raval, V. H., Kailasa, S. K., & Malek, N. I. (2021) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2021.117396 · Cited by 45
Carbamate Prodrug Concept for Hydroxamate HDAC Inhibitors
Schlimme, S., Hauser, A., Carafa, V., Heinke, R., Kannan, S., Stolfa, D. A., Cellamare, S., Carotti, A., Altucci, L., Jung, M., et al. (2011) · ChemMedChem · doi:10.1002/cmdc.201100007 · Cited by 48
The Epigenetic Modifier, Valproic Acid, Enhances Radiation Sensitivity
Karagiannis, T. C., Kurup, H. K. N., & El‐Osta, A. (2006) · Epigenetics · doi:10.4161/epi.1.3.2896 · Cited by 53
Syntheses and Biological Activity of Amamistatin B and Analogs
Fennell, K. A., Möllmann, U., & Miller, M. J. (2008) · The Journal of Organic Chemistry · doi:10.1021/jo7020532 · Cited by 48
Expression and functional characterization of recombinant human HDAC1 and HDAC3
Li, J., Staver, M. J., Curtin, M. L., Holms, J. H., Frey, R. R., Edalji, R. P., Smith, R. A., Michaelides, M. R., Davidsen, S. K., & Glaser, K. B. (2004) · Life Sciences · doi:10.1016/j.lfs.2003.09.070 · Cited by 49
Degraders in epigenetic therapy: PROTACs and beyond
Dai, X., Ji, S., Fu, M., Liu, G.-Z., Liu, H., Wang, S., Shen, L., Wang, N., Herdewijn, P. A., Zheng, Y., et al. (2024) · Theranostics · doi:10.7150/thno.92526 · Cited by 51
“Additionally, HDACs exhibit a strong affinity for negatively charged DNA, enabling them to tightly bind to it [144].”
In Vivo Application of Histone Deacetylase Inhibitor Trichostatin‐A Impairs Murine Male Meiosis
Fenic, I., Hossain, H., Sonnack, V., Tchatalbachev, S., Thierer, F., Trapp, J., Failing, K., Edler, K. S., Bergmann, M., Jung, M., et al. (2008) · Journal of Andrology · doi:10.2164/jandrol.107.003848 · Cited by 50
“In immortalized somatic cells, TSA is able to induce cell cycle arrest followed by either differentiation or apoptosis (Marks et al, 2000) because of selective transcriptional stimulation of genes that negatively control the cell cycle (Johnstone, 2002).”
Background
Metadata
- Authors
- Johnstone, R. W.
- Affiliations
- Peter MacCallum Cancer Centre (AU)
- Corresponding author
- Johnstone, Ricky W.
- ORCID
- Johnstone, Ricky W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2002-04
- Volume
- 1
- Issue
- 4
- Pages
- 287-299
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1971621147
- Cited by
- 1,515
- References
- 121
- Citations by year
- 2026: 9 · 2025: 21 · 2024: 23 · 2023: 46 · 2022: 35 · 2021: 59 · 2020: 50 · 2019: 55 · 2018: 38 · 2017: 65 · 2016: 50 · 2015: 64 · 2014: 54 · 2013: 81 · 2012: 94
- FWCI
- 5.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- National Health and Medical Research Council
- National Medical Research Council
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- histone deacetylase inhibitors, histone acetyltransferase, chromatin remodeling, gene expression regulation, aberrant transcription, tumor cell growth inhibition, cancer therapy
- MeSH terms
- Acetylation, Animals, Antineoplastic Agents, Cell Differentiation, Chromatin, Clinical Trials as Topic, Enzyme Inhibitors, Histones, Humans, Neoplasms, Gene Expression Regulation, Neoplastic, Apoptosis, DNA Methylation, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.